Search research articles
Contact Us
Filters
Showing results (301-310 of 350) with videos related to
Page
of 35
Sort By:
European Journal of Gastroenterology & Hepatology
|
November 18, 2015
Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity
Katja Deterding, Norbert Grüner, Peter Buggisch, et al.
Gastroenterology
|
March 26, 2010
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection
Kerstin A Stegmann, Niklas K Björkström, Heike Veber, et al.
Journal of Viral Hepatitis
|
November 13, 2020
A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction
Olympia E Anastasiou, Cihan Yurdaydin, Benjamin Maasoumy, et al.
The Lancet. Infectious Diseases
|
March 26, 2013
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial
Katja Deterding, Norbert Grüner, Peter Buggisch, et al.
Alimentary Pharmacology & Therapeutics
|
January 19, 2021
Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis
Maurizia R Brunetto, Ivana Carey, Benjamin Maasoumy, et al.
Journal of Hepatology
|
May 18, 2019
Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells
Joana Dias, Julia Hengst, Tiphaine Parrot, et al.
Frontiers in Immunology
|
April 1, 2022
Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern
Ivan Odak, Christian R Schultze-Florey, Swantje I Hammerschmidt, et al.
Advances in Therapy
|
May 11, 2022
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
Markus Cornberg, Adriana Ahumada, Alessio Aghemo, et al.
The Lancet. Infectious Diseases
|
December 29, 2016
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study
Katja Deterding, Christoph D Spinner, Eckart Schott, et al.
Plos One
|
July 30, 2014
Anti-HDV IgM as a marker of disease activity in hepatitis delta
Anika Wranke, Benjamin Heidrich, Stefanie Ernst, et al.
Page
of 35
Search research articles
Search
Showing results (301-310 of 350) with videos related to
Sort By:
Page
of 35
European Journal of Gastroenterology & Hepatology
|
November 18, 2015
Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity
Katja Deterding, Norbert Grüner, Peter Buggisch, et al.
Gastroenterology
|
March 26, 2010
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection
Kerstin A Stegmann, Niklas K Björkström, Heike Veber, et al.
Journal of Viral Hepatitis
|
November 13, 2020
A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction
Olympia E Anastasiou, Cihan Yurdaydin, Benjamin Maasoumy, et al.
The Lancet. Infectious Diseases
|
March 26, 2013
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial
Katja Deterding, Norbert Grüner, Peter Buggisch, et al.
Alimentary Pharmacology & Therapeutics
|
January 19, 2021
Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis
Maurizia R Brunetto, Ivana Carey, Benjamin Maasoumy, et al.
Journal of Hepatology
|
May 18, 2019
Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells
Joana Dias, Julia Hengst, Tiphaine Parrot, et al.
Frontiers in Immunology
|
April 1, 2022
Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern
Ivan Odak, Christian R Schultze-Florey, Swantje I Hammerschmidt, et al.
Advances in Therapy
|
May 11, 2022
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
Markus Cornberg, Adriana Ahumada, Alessio Aghemo, et al.
The Lancet. Infectious Diseases
|
December 29, 2016
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study
Katja Deterding, Christoph D Spinner, Eckart Schott, et al.
Plos One
|
July 30, 2014
Anti-HDV IgM as a marker of disease activity in hepatitis delta
Anika Wranke, Benjamin Heidrich, Stefanie Ernst, et al.
Page
of 35